mRNA Vaccines: From Pandemic to the War Against Cancer
mRNA technology proved its power during the COVID-19 pandemic with Pfizer-BioNTech and Moderna vaccines. Now, scientists are applying this platform to develop personalized cancer vaccines — a breakthrough that could completely change how we treat cancer.
How mRNA Cancer Vaccines Work
Unlike traditional preventive vaccines, mRNA cancer vaccines are designed specifically for each patient. Doctors analyze the tumor genome, identify characteristic mutant proteins (neoantigens), then synthesize mRNA encoding these proteins. When injected, the immune system learns to recognize and destroy cancer cells carrying similar mutations.
Promising Clinical Trial Results
Moderna and Merck Phase II trial on melanoma patients showed that mRNA vaccine combined with Keytruda immunotherapy reduced recurrence or death risk by 44% compared to Keytruda alone. BioNTech is also testing personalized vaccines for pancreatic, colorectal, and lung cancers.
The Future of mRNA Vaccines in Vietnam
The National Institute of Hygiene and Epidemiology and VinBioCare are researching domestic mRNA vaccine platforms. While still far from producing personalized cancer vaccines, this is an important first step for Vietnam to access the worlds most advanced biomedical technology. The estimated cost per personalized vaccine course is currently around $100,000, but is expected to decrease significantly as the technology matures.
Related Articles

Vaccine mRNA hoạt động như thế nào? Giải thích đơn giản
Công nghệ mRNA đã tạo ra bước ngoặt trong cuộc chiến chống COVID-19. Video giải thích cơ chế hoạt động của vaccine mRNA một cách dễ hiểu.
7/4/2026

Robot phẫu thuật Da Vinci: Tương lai của phẫu thuật xâm lấn tối thiểu
Hệ thống robot Da Vinci đang thay đổi phẫu thuật hiện đại. Tìm hiểu cách robot hỗ trợ bác sĩ thực hiện ca mổ chính xác hơn.
7/4/2026

Tế bào gốc trong điều trị bệnh Parkinson: Hy vọng mới từ phòng thí nghiệm
iPSC stem cell transplant trials at Kyoto University show promising results for Parkinson treatment. Clinical approval expected by 2030-2035.
7/4/2026